Intra-Articular Corticosteroid Injections for Knee Osteoarthritis

Preferred Corticosteroid Agent

Triamcinolone hexacetonide is strongly recommended as the preferred intra-articular corticosteroid for joint injections, demonstrating more durable clinical responses than triamcinolone acetonide in randomized trials and large observational studies 1, 2, 3
This agent has been shown to provide superior outcomes in maintaining remission compared to alternative injectable glucocorticoids 4

Triamcinolone hexacetonide has been commercially unavailable in the US for several years, forcing clinicians to use less effective alternatives 1, 2, 4
The FDA recently allowed importation of one specific formulation of triamcinolone hexacetonide for joint injections to address this unmet medical need 1, 2, 3

Intra-articular corticosteroid injections are strongly recommended for knee osteoarthritis by the American College of Rheumatology, with Level 1A+ evidence supporting their use 5

Corticosteroid injections may contribute to cartilage loss, but this finding lacks clinical significance because changes in cartilage thickness were not associated with worsening pain, function, or other radiographic features 5
Providers must consider potential long-term negative effects on bone health, joint structure, and meniscal thickness with repeat administration 6

Intra-articular corticosteroid injections are conditionally recommended over hyaluronic acid preparations, as the evidence for glucocorticoid efficacy is considerably higher quality than for other agents 5

The 2021 VA/DoD guidelines suggest offering corticosteroid injections for persistent knee OA pain as second-line or combination therapy, with effects being time-limited without long-term improvement at 2-year follow-up 7, 8
Injections are particularly indicated for acute exacerbations of knee pain, especially when accompanied by effusion, with the American College of Rheumatology strongly recommending intra-articular corticosteroid injections for knee osteoarthritis 7, 8, 9, 10

Avoid corticosteroid injection for 3 months preceding joint replacement surgery due to theoretical infection risk, though evidence for elevated risk is limited, and consider potential long-term negative effects on bone health, joint structure, and meniscal thickness with repeat administration 7, 8
Knee injections do not require ultrasound guidance, and strict aseptic technique is mandatory, with the injection made into the synovial space for full anti-inflammatory effect 7, 8

The American College of Rheumatology recommends dosing based on the size of involved joints, with lower doses used for smaller joints, though specific dosing for hand osteoarthritis is not well established 11, 12
Intra-articular corticosteroids are strongly indicated for acute exacerbations of knee pain, especially with effusion, in patients with knee osteoarthritis 13
Intra-articular corticosteroids can be used in combination with oral corticosteroids, NSAIDs, or colchicine for severe presentations in patients with knee osteoarthritis 11, 12

Patients should avoid overuse of the injected joint for 24 hours, but complete immobilization is discouraged, to minimize potential adverse effects 13

The decision to reinject should consider benefits from previous injections and individualized factors, including treatment options, compound used, systemic treatment, and comorbidities, to minimize cumulative adverse effects 13

The American Academy of Orthopaedic Surgeons found considerable evidence supporting corticosteroid injections with 19 high-quality and 6 moderate-quality studies 14
Triamcinolone acetonide (Kenalog) at 40 mg is the standard alternative when hexacetonide is unavailable, providing pain relief at 6 weeks but not sustained at 12 weeks 15, 16
Methylprednisolone shows improved knee pain and function at 4 and 24 weeks, demonstrating longer duration than triamcinolone acetonide 15, 16

Intra-articular corticosteroids demonstrate strong short-term efficacy (effect size 1.27 at 7 days) but benefits are time-limited 17, 18
The duration of benefit is typically only 3 months without long-term improvement at 2-year follow-up 15, 16

Avoid corticosteroid injection for 3 months preceding joint replacement surgery due to theoretical infection risk, though systematic review found limited data describing elevated risk 15, 16
Consider potential long-term negative effects on bone health, joint structure, and meniscal thickness with repeat administration 15, 16